The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

Researchers used advanced AI to see if any FDA-approved medications could potentially reverse one of the mutations behind dilated cardiomyopathy. Risedronate, a popular osteoporosis medication, is the one candidate that got the job done.

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

Cardiologists have warned for years that healthy adults with no family history of CVD should not be taking low-dose aspirin every day—but as the saying goes, old habits die hard. 

The difference in atrial fibrillation risk was unexpected, surprising researchers.

“It has the added advantage of avoiding oral anticoagulation drugs and the risks associated with lifelong anticoagulation," one researcher explained. "In fact, most of our patients are not on any cardiac medications following one year after surgery.”

The National Committee for Quality Assurance is taking public comment on the health plan quality metric until March 13. 

In an SEC filing, the insurer argues that requests by investors for more reporting on claims denials may already be satisfied through its regulatory compliance processes.